Literature DB >> 21078301

Universal antibodies against the highly conserved influenza fusion peptide cross-neutralize several subtypes of influenza A virus.

Anwar M Hashem1, Gary Van Domselaar, Changgui Li, Junzhi Wang, Yi-Min She, Terry D Cyr, Jianhua Sui, Runtao He, Wayne A Marasco, Xuguang Li.   

Abstract

The fusion peptide of influenza viral hemagglutinin plays a critical role in virus entry by facilitating membrane fusion between the virus and target cells. As the fusion peptide is the only universally conserved epitope in all influenza A and B viruses, it could be an attractive target for vaccine-induced immune responses. We previously reported that antibodies targeting the first 14 amino acids of the N-terminus of the fusion peptide could bind to virtually all influenza virus strains and quantify hemagglutinins in vaccines produced in embryonated eggs. Here we demonstrate that these universal antibodies bind to the viral hemagglutinins in native conformation presented in infected mammalian cell cultures and neutralize multiple subtypes of virus by inhibiting the pH-dependant fusion of viral and cellular membranes. These results suggest that this unique, highly-conserved linear sequence in viral hemagglutinin is exposed sufficiently to be attacked by the antibodies during the course of infection and merits further investigation because of potential importance in the protection against diverse strains of influenza viruses. Crown
Copyright © 2010. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21078301     DOI: 10.1016/j.bbrc.2010.11.030

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  25 in total

1.  Quantitative analyses of all influenza type A viral hemagglutinins and neuraminidases using universal antibodies in simple slot blot assays.

Authors:  Caroline Gravel; Changgui Li; Junzhi Wang; Anwar M Hashem; Bozena Jaentschke; Gary Van Domselaar; Runtao He; Xuguang Li
Journal:  J Vis Exp       Date:  2011-04-04       Impact factor: 1.355

2.  A virus-like particle that elicits cross-reactive antibodies to the conserved stem of influenza virus hemagglutinin.

Authors:  Anette Schneemann; Jeffrey A Speir; Gene S Tan; Reza Khayat; Damian C Ekiert; Yumiko Matsuoka; Ian A Wilson
Journal:  J Virol       Date:  2012-08-15       Impact factor: 5.103

3.  Immunogenicity of low-pH treated whole viral influenza vaccine.

Authors:  Fu-Shi Quan; Zhu-Nan Li; Min-Chul Kim; Dan Yang; Richard W Compans; David A Steinhauer; Sang-Moo Kang
Journal:  Virology       Date:  2011-06-30       Impact factor: 3.616

4.  A highly conserved neutralizing epitope on group 2 influenza A viruses.

Authors:  Damian C Ekiert; Robert H E Friesen; Gira Bhabha; Ted Kwaks; Mandy Jongeneelen; Wenli Yu; Carla Ophorst; Freek Cox; Hans J W M Korse; Boerries Brandenburg; Ronald Vogels; Just P J Brakenhoff; Ronald Kompier; Martin H Koldijk; Lisette A H M Cornelissen; Leo L M Poon; Malik Peiris; Wouter Koudstaal; Ian A Wilson; Jaap Goudsmit
Journal:  Science       Date:  2011-07-07       Impact factor: 47.728

5.  The universal epitope of influenza A viral neuraminidase fundamentally contributes to enzyme activity and viral replication.

Authors:  Tracey M Doyle; Bozena Jaentschke; Gary Van Domselaar; Anwar M Hashem; Aaron Farnsworth; Nicole E Forbes; Changgui Li; Junzhi Wang; Runtao He; Earl G Brown; Xuguang Li
Journal:  J Biol Chem       Date:  2013-05-03       Impact factor: 5.157

Review 6.  Targeting B cell responses in universal influenza vaccine design.

Authors:  Kaval Kaur; Meghan Sullivan; Patrick C Wilson
Journal:  Trends Immunol       Date:  2011-09-21       Impact factor: 16.687

7.  Functional Study of the C-Terminal Part of the Hepatitis C Virus E1 Ectodomain.

Authors:  Rehab I Moustafa; Juliano G Haddad; Lydia Linna; Xavier Hanoulle; Véronique Descamps; Ahmed Atef Mesalam; Thomas F Baumert; Gilles Duverlie; Philip Meuleman; Jean Dubuisson; Muriel Lavie
Journal:  J Virol       Date:  2018-09-26       Impact factor: 5.103

8.  Recombinant HA1 produced in E. coli forms functional oligomers and generates strain-specific SRID potency antibodies for pandemic influenza vaccines.

Authors:  Surender Khurana; Christopher Larkin; Swati Verma; Manju B Joshi; Juan Fontana; Alasdair C Steven; Lisa R King; Jody Manischewitz; William McCormick; Rajesh K Gupta; Hana Golding
Journal:  Vaccine       Date:  2011-06-23       Impact factor: 3.641

9.  A broadly neutralizing human monoclonal antibody is effective against H7N9.

Authors:  Kannan Tharakaraman; Vidya Subramanian; Karthik Viswanathan; Susan Sloan; Hui-Ling Yen; Dale L Barnard; Y H Connie Leung; Kristy J Szretter; Tyree J Koch; James C Delaney; Gregory J Babcock; Gerald N Wogan; Ram Sasisekharan; Zachary Shriver
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-17       Impact factor: 11.205

10.  Mechanistic study of broadly neutralizing human monoclonal antibodies against dengue virus that target the fusion loop.

Authors:  Joshua M Costin; Elena Zaitseva; Kristen M Kahle; Cindo O Nicholson; Dawne K Rowe; Amanda S Graham; Lindsey E Bazzone; Greg Hogancamp; Marielys Figueroa Sierra; Rachel H Fong; Sung-Tae Yang; Li Lin; James E Robinson; Benjamin J Doranz; Leonid V Chernomordik; Scott F Michael; John S Schieffelin; Sharon Isern
Journal:  J Virol       Date:  2012-10-17       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.